Kymera Therapeutics (NASDAQ:KYMR) Stock Price Up 4.5%

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s share price rose 4.5% on Thursday . The stock traded as high as $35.32 and last traded at $35.28. Approximately 318,646 shares were traded during trading, a decline of 57% from the average daily volume of 742,994 shares. The stock had previously closed at $33.76.

Analyst Upgrades and Downgrades

KYMR has been the topic of several recent analyst reports. JPMorgan Chase & Co. lifted their target price on Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Bank of America downgraded Kymera Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $45.00 to $30.00 in a research note on Wednesday, January 3rd. Wolfe Research assumed coverage on Kymera Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Truist Financial boosted their price objective on Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, Stifel Nicolaus boosted their price objective on Kymera Therapeutics from $35.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $39.89.

Kymera Therapeutics Price Performance

The stock has a 50-day moving average of $39.20 and a two-hundred day moving average of $27.68.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.19. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. The business had revenue of $47.90 million during the quarter, compared to analyst estimates of $41.94 million. During the same quarter last year, the company posted ($0.60) EPS. Kymera Therapeutics’s revenue for the quarter was up 197.5% on a year-over-year basis. Research analysts expect that Kymera Therapeutics, Inc. will post -3.13 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Bruce N. Jacobs sold 3,934 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $41.86, for a total value of $164,677.24. Following the completion of the sale, the chief financial officer now directly owns 142,351 shares of the company’s stock, valued at approximately $5,958,812.86. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director Jeffrey W. Albers sold 10,000 shares of the stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $30.05, for a total value of $300,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Bruce N. Jacobs sold 3,934 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $41.86, for a total value of $164,677.24. Following the completion of the sale, the chief financial officer now directly owns 142,351 shares of the company’s stock, valued at $5,958,812.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 484,051 shares of company stock valued at $19,924,711. Corporate insiders own 16.67% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Hong Kong Ltd purchased a new stake in shares of Kymera Therapeutics during the 1st quarter worth about $53,000. Amundi purchased a new stake in shares of Kymera Therapeutics during the 4th quarter worth about $49,000. Advisors Asset Management Inc. purchased a new stake in shares of Kymera Therapeutics during the 4th quarter worth about $58,000. Royal Bank of Canada increased its holdings in shares of Kymera Therapeutics by 30.0% during the 2nd quarter. Royal Bank of Canada now owns 2,773 shares of the company’s stock valued at $64,000 after acquiring an additional 640 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Kymera Therapeutics by 65.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,899 shares of the company’s stock valued at $67,000 after acquiring an additional 1,146 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.